Microbix Biosystems (TSE:MBX) Stock Crosses Above Fifty Day Moving Average – Should You Sell?

Microbix Biosystems Inc. (TSE:MBX) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of C$0.25 and traded as high as C$0.30. Microbix Biosystems shares last traded at C$0.30, with a volume of 44,974 shares changing hands.

Microbix Biosystems Stock Performance

The firm has a market capitalization of C$41.25 million, a PE ratio of -7.32 and a beta of 0.70. The company has a debt-to-equity ratio of 27.03, a current ratio of 5.35 and a quick ratio of 5.57. The company’s fifty day simple moving average is C$0.25 and its 200 day simple moving average is C$0.24.

Microbix Biosystems (TSE:MBX) last released its quarterly earnings data on Thursday, May 14th. The company reported C($0.01) EPS for the quarter. The business had revenue of C$3.38 million for the quarter. Microbix Biosystems had a negative net margin of 38.62% and a negative return on equity of 21.02%. As a group, equities research analysts expect that Microbix Biosystems Inc. will post 0.02 EPS for the current fiscal year.

Insider Buying and Selling

In other Microbix Biosystems news, Director Martin Marino acquired 115,000 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were acquired at an average cost of C$0.28 per share, with a total value of C$32,200.00. Following the completion of the acquisition, the director directly owned 2,000,167 shares in the company, valued at C$560,046.76. This trade represents a 6.10% increase in their ownership of the stock. Insiders have bought 230,500 shares of company stock worth $62,325 over the last quarter. 14.00% of the stock is owned by corporate insiders.

Microbix Biosystems Company Profile

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.